In her closing argument last month in a Texas courtroom, Merck lawyer Gerry Lowry said that science is "what this [Vioxx] case is all about." The team representing the pharmaceutical giant presented reams of data to show that Vioxx was not to blame in the death of the plaintiff's husband, a 59-year-old triathelete. So when 10 of 12 jurors decided that Merck was guilty of producing and marketing a drug that could be deadly, some reports painted the outcome as a triumph of hot emotion over cold facts.
But observers say that neither legal team dealt forthrightly with two important scientific questions: How safe are Vioxx and similar drugs, and did the victim, a Wal-Mart employee named Robert Ernst, actually die from one of the drug's known side effects? "Both sides avoided the scientific complexity," says Garret FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania in Philadelphia who has criticized COX-2 inhibitors, the class of drugs to which Vioxx belongs, despite having received research funding from Merck. That complexity, which received only minimal attention during the 5-week trial, centers on how Vioxx affects the heart-and how new techniques can pinpoint death by blood clot even if it's not visible during a standard autopsy.
Carol Ernst's suit on behalf of her husband, who died in 2001 after taking Vioxx for 8 months, is one of more than 4000 pending suits against the one-time blockbuster drug that Merck pulled from the market last September after a study showed an increased risk of heart attacks and strokes. The jury's brief deliberations and the size of the verdict-$253 million, some 10 times what Texas law allows-led some observers to conclude that jurors disregarded the factual evidence in favor of emotional arguments put forth by the plaintiff's attorney Mark Lanier. "The jury never quite got it-a lot of people just don't want to hear data," says Thomas Wheeler, a pathologist at Baylor College of Medicine in Houston, Texas, who testified as a paid witness on Merck's behalf. In fact, jurors told the Wall Street Journal after the verdict that the science presented during the trial "sailed right over their heads."
But questioning the jury's scientific competence-a majority had high school educations-may be missing a more important issue. "It is all too easy to blame the jury for being stupid," says Shari Diamond, a research psychologist and law professor at Northwestern University in Chicago. She and others believe the jury was convinced by studies showing that Vioxx can cause abnormally high rates of heart attack and stroke. Neil Vidmar, a law professor and psychologist at Duke University in Durham, North Carolina, adds that although "science seemed to be the issue" during the trial, "I suspect the strongest evidence [against the defense] was that Merck had covered up." Internal memos and e-mails cited in the trial show that Merck scientists were aware of cardiovascular concerns about Vioxx long before a 2000 article in The New England Journal of Medicine first raised the issue publicly.
Unlike older anti-inflammatory drugs, Vioxx and other COX-2 inhibitors are thought less likely to upset the stomach or cause gastric bleeding. The compoundswhich include Pfizer's Bextra and Celebrex-inhibit on a narrower set of inflammatory enzymes than their painkilling predecessors do. That action, researchers believe, may instigate and accelerate blood clotting that could lead to heart attacks and strokes (Science, 15 October 2004, p. 384) .
However, Ernst's death certificate listed arrhythmia rather than a heart attack brought on by a blood clot. Vioxx or other COX-2 drugs have not been associated in any study with arrhythmia. And the autopsy showed no signs of clotting that could have generated a heart attack. Wheeler, a pathologist who has specialized in prostate rather than heart research, told the jury that Vioxx could not have been responsible for Ernst's death. "And I stand by that," he told Science last week.
But FitzGerald and others aren't so sure. Although there was no evidence of a clot, he says, "that doesn't mean [Ernst] didn't have one." Eric Topol, a cardiovascular researcher at the Cleveland Clinic in Ohio who has been a vocal critic of Vioxx, notes that clots traditionally have been difficult to track because they sometimes dissolve only to reform. "This is not a static phenomenon." Clots also can embolize, or shower downstream, leaving little trace. It's even possible to find clues of a vanished clot using microscopic examinations of heart tissue, a method pioneered by the late Michael Davies. Such a fine-tuned autopsy was not performed on Ernst. As a result, says Topol, "they spent 5 weeks discussing the wrong topic. Merck's general counsel Kenneth Frazier said after the trial that "the jury was allowed to hear testimony that was not based on reliable science and that was irrelevant." He vowed to appeal that case, in part on that basis, and to fight some 4200 pending cases "one by one," although last week he told The New York Times that Merck might be willing to settle select cases.
Yet even if upcoming trials involve heart attack and stroke victims, they inevitably will require sorting through many complex factors, says Topol. And a courtroom, Wheeler notes, is a difficult place to debate complicated research issues. So even if science is what the Vioxx debate is all about, it's a strain developed for the courtroom, not the lab.
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